Skip to main content

Aprea Therapeutics, Inc. (APRE)

NASDAQ: APRE · IEX Real-Time Price · USD
4.63
+0.10 (2.21%)
After-hours:Sep 24, 2021 7:59 PM EDT
4.53
0.03 (0.67%)
At close: Sep 24, 4:00 PM
Market Cap99.68M
Revenue (ttm)n/a
Net Income (ttm)-47.63M
Shares Out21.19M
EPS (ttm)-2.25
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,095,421
Open4.50
Previous Close4.50
Day's Range4.41 - 4.76
52-Week Range3.17 - 30.99
Betan/a
AnalystsHold
Price Target4.00 (-11.7%)
Est. Earnings DateNov 4, 2021

About APRE

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung ca...

IndustryBiotechnology
IPO DateOct 3, 2019
Employees11
Stock ExchangeNASDAQ
Ticker SymbolAPRE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for APRE stock is "Hold." The 12-month stock price forecast is 4.00, which is a decrease of -11.70% from the latest price.

Price Target
$4.00
(-11.70% downside)
Analyst Consensus: Hold

News

Aprea Therapeutics Stock Jumps After Eprenetapopt Combo Data Presentation At ESMO

Aprea Therapeutics Inc (NASDAQ: APRE) presented data at the European Society of Medical Oncology (ESMO) Congress 2021 from its Phase 1/2 trial in advanced solid tumors.  The trial is evaluating the safe...

4 days ago - Benzinga

Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Cong...

BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mu...

4 days ago - GlobeNewsWire

Is the Options Market Predicting a Spike in Aprea Therapeutics (APRE) Stock?

Investors need to pay close attention to Aprea Therapeutics (APRE) stock based on the movements in the options market lately.

4 days ago - Zacks Investment Research

Best Penny Stocks To Buy? 5 To Watch This Week With Biotech Catalysts

Penny stocks with important dates to know this week. The post Best Penny Stocks To Buy?

Other symbols:CAPRCFMSSPPIVSTM
5 days ago - PennyStocks

Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations

BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mut...

1 month ago - GlobeNewsWire

Aprea Therapeutics Drops After FDA Clinical Hold On Another Blood Cancer Study

After instituting a partial clinical hold on Aprea Therapeutics Inc's (NASDAQ: APRE) myeloid malignancies program, the FDA has placed a clinical hold on Aprea's lymphoid malignancy study.  The trial is ...

1 month ago - Benzinga

Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program

BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant ...

1 month ago - GlobeNewsWire

Aprea Therapeutics Stock Drops On FDA Clinical Hold On Eprenetapopt Myeloid Malignancy Trials

The FDA has instituted a partial clinical hold on Aprea Therapeutics Inc's (NASDAQ: APRE) clinical trials of eprenetapopt (APR-246) combined with azacitidine in its myeloid malignancy programs.  Approxi...

1 month ago - Benzinga

Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs

BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant ...

1 month ago - GlobeNewsWire

Aprea Stock Pops As Eprenetapopt Combo Regime Shows 58% Relapse-Free Survival, 79% Overall Survival At 1-Year Post-Tr...

Aprea Therapeutics Inc (NASDAQ: APRE) has announced results from its Phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant myelodysp...

2 months ago - Benzinga

Implied Volatility Surging for Aprea (APRE) Stock Options

Investors need to pay close attention to Aprea (APRE) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal

Aprea (APRE) announces that treatment with a combination regimen of its pipeline candidate, eprenetapopt, achieves 37% complete response rate in acute myeloid leukemia patients.

3 months ago - Zacks Investment Research

Karolinska Development's portfolio company Aprea Therapeutics lead candidate drug eprenetapopt reaches primary effica...

STOCKHOLM, SWEDEN – June 17, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Aprea Therapeutics has reported positive outcomes in an ongoing Phase 1/2...

3 months ago - GlobeNewsWire

Best Biotech Penny Stocks to Buy? Here's 3 That Are Well Funded

Looking for well-funded biotech penny stocks? Check these 3 small-caps out The post Best Biotech Penny Stocks to Buy?

Other symbols:ITRMPOAI
3 months ago - PennyStocks

Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today

Kindred Biosciences, Inc. (NASDAQ: KIN), Aprea Therapeutics, Inc. (NASDAQ: APRE), Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) and Inhibikase Therapeutics, Inc. (NASDAQ: IKT) are among the biggest bio...

Other symbols:IKT
3 months ago - Benzinga

APRE Stock: The Big Leukemia Study News That Has Aprea Therapeutics Skyrocketing Today

Aprea Therapeutics (APRE) stock is seeing major gains on Wednesday after revealing results from a recent Phase 1/2 trial. The post APRE Stock: The Big Leukemia Study News That Has Aprea Therapeutics Sky...

3 months ago - InvestorPlace

Aprea Therapeutics Stock Is Trading Higher As Eprenetapopt Triplet Therapy Achieves 37% CR Rate In Leukemia Patients

Aprea Therapeutics Inc (NASDAQ: APRE) has announced that the Phase 1/2 trial evaluating eprenetapopt in acute myeloid leukemia (AML) has met the pre-specified primary efficacy endpoint of complete remis...

3 months ago - Benzinga

Why Aprea Therapeutics Shares Are Surging Today

Aprea Therapeutics Inc (NASDAQ:APRE) shares are trading higher by 46% at $7.07 after the company announced the Phase 1/2 trial of eprenetapopt with venetoclax and azacitidine in TP53 mutant AML met the ...

3 months ago - Benzinga

Aprea Therapeutics to Participate in the 2021 Oppenheimer Rare & Orphan Disease Summit

BOSTON, May 21, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant t...

4 months ago - GlobeNewsWire

Aprea Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference

BOSTON, May 18, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant t...

4 months ago - GlobeNewsWire

Aprea Therapeutics Reports First Quarter 2021 Financial Results and Provides Update on Business Operations

BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the muta...

4 months ago - GlobeNewsWire

Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021

BOSTON, April 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mu...

5 months ago - GlobeNewsWire

Karolinska Development's portfolio company Aprea Therapeutics receives orphan drug designation for eprenetapopt in AML

STOCKHOLM, SWEDEN – April 9, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Aprea Therap...

5 months ago - GlobeNewsWire

Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia ...

BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mu...

5 months ago - GlobeNewsWire

What's Going On With APRE Stock And IMMP Stock Today?

Aprea Therapeutics Inc (NASDAQ: APRE) shares are trading higher after the company announced that it received FDA Orphan Drug Designation for its eprenetapopt for the treatment of acute myeloid leukemia....

Other symbols:IMMP
5 months ago - Benzinga